Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alim R Devani

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Journal of Cutaneous Medicine and Surgery|September 30, 2021
Incidence of COVID-19 in Patients With Chronic Idiopathic Urticaria and Asthma on Omalizumab: A Multicentre Retrospective Cohort StudyAbrahim Abduelmula, Jorge R Georgakopoulos, Asfandyar Mufti, et al.
Journal of the American Academy of Dermatology|January 20, 2025
Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: A 52-week multicenter retrospective reviewSiddhartha Sood, Alexander Rimke, Brian D Rankin, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|June 24, 2024
Effectiveness and Safety of Upadacitinib in Adolescent and Adult Patients with Atopic Dermatitis: An Analysis of Short-Term (Week 8-20) Data from a Real-World Multicenter Retrospective ReviewBrian D Rankin, Siddhartha Sood, Ye-Jean Park, et al.
Journal of the American Academy of Dermatology|August 25, 2024
Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: A 16-week multicenter retrospective reviewSiddhartha Sood, Alexander Rimke, Brian D Rankin, et al.
American Journal of Clinical Dermatology|February 3, 2025
Real-World Experience of Bimekizumab for Plaque Psoriasis in Adult Patients with Prior Exposure to Interleukin-23 Inhibitors: A Multicenter Retrospective StudySiddhartha Sood, Alexander Rimke, Brian D Rankin, et al.
Journal of the American Academy of Dermatology|February 15, 2025
Response to Potestio et al., "Comment on Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: A 16-week multicenter retrospective review"Siddhartha Sood, Alexander Rimke, Brian D Rankin, et al.
The Journal of Dermatological Treatment|April 21, 2022
Incidence and prognosis of COVID-19 in patients with atopic diseases on dupilumab: a multicentre retrospective cohort studyBrian D Rankin, Jorge-Ryan Georgakopoulos, Muskaan Sachdeva, et al.
Journal of Cutaneous Medicine and Surgery|June 5, 2026
Real-World Effectiveness and Safety of Deucravacitinib for Adult Patients with Plaque Psoriasis: A 16-Week Multicenter Retrospective Study of Monotherapy and Combination TherapySiddhartha Sood, Ahmed Bagit, Khalad Maliyar, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|October 24, 2024
Effectiveness and Safety of Upadacitinib in Adolescent and Adult Patients with Atopic Dermatitis: An Analysis of Long-Term (Week 52) Data from a Real-World Multicenter Retrospective ReviewBrian D Rankin, Siddhartha Sood, Ye-Jean Park, et al.
Journal of the American Academy of Dermatology|June 17, 2024
Real-world experience of bimekizumab for adult patients with plaque psoriasis: A 52-week multicenter retrospective studySiddhartha Sood, Alexander Rimke, Brian D Rankin, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Journal of Cutaneous Medicine and Surgery|September 30, 2021
Incidence of COVID-19 in Patients With Chronic Idiopathic Urticaria and Asthma on Omalizumab: A Multicentre Retrospective Cohort StudyAbrahim Abduelmula, Jorge R Georgakopoulos, Asfandyar Mufti, et al.
Journal of the American Academy of Dermatology|January 20, 2025
Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: A 52-week multicenter retrospective reviewSiddhartha Sood, Alexander Rimke, Brian D Rankin, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|June 24, 2024
Effectiveness and Safety of Upadacitinib in Adolescent and Adult Patients with Atopic Dermatitis: An Analysis of Short-Term (Week 8-20) Data from a Real-World Multicenter Retrospective ReviewBrian D Rankin, Siddhartha Sood, Ye-Jean Park, et al.
Journal of the American Academy of Dermatology|August 25, 2024
Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: A 16-week multicenter retrospective reviewSiddhartha Sood, Alexander Rimke, Brian D Rankin, et al.
American Journal of Clinical Dermatology|February 3, 2025
Real-World Experience of Bimekizumab for Plaque Psoriasis in Adult Patients with Prior Exposure to Interleukin-23 Inhibitors: A Multicenter Retrospective StudySiddhartha Sood, Alexander Rimke, Brian D Rankin, et al.
Journal of the American Academy of Dermatology|February 15, 2025
Response to Potestio et al., "Comment on Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: A 16-week multicenter retrospective review"Siddhartha Sood, Alexander Rimke, Brian D Rankin, et al.
The Journal of Dermatological Treatment|April 21, 2022
Incidence and prognosis of COVID-19 in patients with atopic diseases on dupilumab: a multicentre retrospective cohort studyBrian D Rankin, Jorge-Ryan Georgakopoulos, Muskaan Sachdeva, et al.
Journal of Cutaneous Medicine and Surgery|June 5, 2026
Real-World Effectiveness and Safety of Deucravacitinib for Adult Patients with Plaque Psoriasis: A 16-Week Multicenter Retrospective Study of Monotherapy and Combination TherapySiddhartha Sood, Ahmed Bagit, Khalad Maliyar, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|October 24, 2024
Effectiveness and Safety of Upadacitinib in Adolescent and Adult Patients with Atopic Dermatitis: An Analysis of Long-Term (Week 52) Data from a Real-World Multicenter Retrospective ReviewBrian D Rankin, Siddhartha Sood, Ye-Jean Park, et al.
Journal of the American Academy of Dermatology|June 17, 2024
Real-world experience of bimekizumab for adult patients with plaque psoriasis: A 52-week multicenter retrospective studySiddhartha Sood, Alexander Rimke, Brian D Rankin, et al.
Pageof 3